1. Review the role of CYP2D6 in opioid metabolism
  2. Review evidence supporting the use of phamacogenomic markers which may predict efficacy, cumulative dosage, and risk of toxicity of codeine, tramadol, oxycodone, hydrocodone, and fentanyl


  1. Discuss the evidence for definitive local treatment of oligometastatic disease  
  2. Discuss the evidence for control of intra-cranial disease with immunotherapy or systemic therapy
Session date: 
02/25/2019 - 12:00pm to 1:00pm CST
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Natalie M. Reizine, MD and Sherin J. Rouhani, MD, PhD